# Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).

> **NCT06550128** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Ausper Biopharma Co., Ltd.** · enrollment: 86 (actual)

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** AHB-137
- **DRUG:** AHB-137 and Placebo
- **DRUG:** AHB-137 (16weeks)

## Key facts

- **NCT ID:** NCT06550128
- **Lead sponsor:** Ausper Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2025-05-26
- **Final completion:** 2026-10-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06550128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06550128, "Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB).". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06550128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*